Revumenib for Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia: Outcomes by Leukemia Type in the Phase 2 AUGMENT-101 Study 1001

Oral Presentation | Dec 6, 2025

Author

Aldoss I, et al.

Congress

American Society of Hematology Annual Meeting 2025

Orlando, Florida | Dec 6 – 9, 2025